Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1275-1279

  Brandes, Alba A ^a   Tosoni, Alicia ^a   Franceschi, Enrico ^a   Sotti, Guido ^a   Frezza, Giampiero ^a   Amistà, Pietro ^a   Morandi, Luca ^a   Spagnolli, Federica ^a   Ermani, Mario ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; COGNITIVE DEFECT; DISEASE COURSE; DNA METHYLATION; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; GENE; GENETIC SUSCEPTIBILITY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; RADIATION FIELD; RADIATION HAZARD; TREATMENT OUTCOME;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; RADIOTHERAPY, ADJUVANT; TUMOR SUPPRESSOR PROTEINS;

EID: 62449258056     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.4969     Document Type: Article

References (20)

1. Wallner KE, Galicich JH, Krol G, et al: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405-1409, 1989
2. Garden AS, Maor MH, Yung WK, et al: Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20:99-110, 1991
3. Schryver AD, Greitz T, Forsby N, et al: Localized shaped field radiotherapy of malignant glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1:713-716, 1976
4. Liang BC, Thornton AF Jr, Sandler HM, et al: Malignant astrocytomas: Focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75:559-563, 1991
5. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911, 1980
6. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
7. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
8. Ataman F, Poortmans P, Stupp R, et al: Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: The individual case review. Eur J Cancer 40:1724-1730, 2004
9. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
10. Palmisano WA, Divine KK, Saccomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000
11. Brandes AA, Tosoni A, Cavallo G, et al: Correlations between 06-methylguanine DNA methyltrans-ferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study. J Clin Oncol 24:4746-4753, 2006
12. Lee SW, Fraass BA, Marsh LH, et al: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43: 79-88, 1999
13. Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569, 2006
14. DeAngelis LM: Chemotherapy for brain tumors: A new beginning. N Engl J Med 352:1036-1038, 2005
15. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
16. Hess CF, Schaaf JC, Kortmann RD, et al: Malignant glioma: Patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146-149, 1994
17. Nakagawa K, Aoki Y, Fujimaki T, et al: High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:1141-1149, 1998
18. Mehta MP, Masciopinto J, Rozental J, et al: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541-549, 1994
19. Chakravarti A, Erkkinen MG, Nestler U, et al: Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 12:4738-4746, 2006
20. Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197, 2008